[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ii-renal-cell-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ii-renal-cell-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100549286","phase-1-yttrium-90-y90-radioembolization-for-the-treatment-of-early-stage-renal-cell-carcinoma-the-renegade-trial-100549286",false,"NCT06432036","Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial","RENEGADE: Radioembolization for Early Stage Renal Cell Carcinoma: An Open-Label, Prospective, Multi-Center, Phase 1\u002F2 Safety Trial","Inclusion Criteria:\n\n* Participants must be aged ≥ 18 years at the time of screening\n* Written informed consent and any locally required authorization (e.g., Health Insurance Portability and accountability Act) obtained from the patient\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n* Life expectancy ≥ 12 months\n* RCC, diagnosed by radiographic imaging and histology\n* Clinical stage of RCC: T1 or T2a, Cancer stage (N0M0)\n* 1-2 solid (\\> 80% solid) target lesions\n* Patient not an ideal candidate for partial nephrectomy or thermal ablation at the time of study entry, based on the decision of the institution's multidisciplinary tumor board. Contraindications for partial nephrectomy include inability to potentially partially resect the kidney, high risk of adverse events due to medical comorbidities, or potential high risk of adverse events due to general anesthesia. Contraindications to thermal ablation include potential inability to technically place ablation probes into the tumor, central tumors which risk thermal injury to the renal collecting system\n* Patient not considered a candidate for long-term active surveillance due to oncologic risk due to tumor growth and\u002For tumor size\n* Patient not considered ideal candidates for radical nephrectomy due to surgical comorbidity and\u002For development of adverse health outcomes\n* Measurable tumor by RECIST 1.1 criteria\n* Absence of bilateral renal tumors\n* Negative serum pregnancy test in females of child-bearing potential; patients who are breast-feeding cannot participate in this trial\n* Hemoglobin ≥ 9.0 g\u002FdL\n* Absolute neutrophil count ≥ 1.5 x 10\\^9\u002FL\n* Absolute lymphocyte count ≥ 1.0 x 10\\^9\u002FL\n* Platelet count ≥ 75 x 10\\^9\u002FL\n* Glomerular filtration rate (GFR) ≥ 45 mL\u002Fmin\u002F1.73 m\\^2\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment\n* Screening mapping angiogram demonstrates successful localization of tumor(s), where catheter placement location(s) would allow Y90 to distribute in the intended treatment area, without venous shunting\n\nExclusion Criteria:\n\n* Any contraindication to angiography or selective renal artery catheterization\n* Screening angiography with cone beam CT (CBCT) shows any arterial flow to the gastrointestinal tract uncorrectable by angiographic techniques\n* Screening angiography with CBCT shows poor tumor targeting that would lead to a dose that does not meet the renal dosing criteria. This typically occurs when a feeding artery to the tumor cannot be identified\n* Screening angiography demonstrates excessive non-tumoral renal parenchyma will be in the treatment field, that the new baseline glomerular filtration rate will be \\\u003C 45 mL\u002Fmin\u002F1.73 m\\^2\n* Screening angiography demonstrates renal venous shunting of iodinated contrast that is immediately visible upon arterial injection\n* Extra-renal metastases, including patients with abdominal lymph nodes \\>1.5 cm in shorter axis, or with lung nodules (single lesion, \\>1 cm, or multiple smaller lesions with a total diameter \\>2 cm)\n* Brain metastases, leptomeningeal carcinomatosis or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry\n* Evidence of any tumor invasion into the renal vein, renal artery, or renal collecting system\n* Any prior radiation therapy to the abdomen, including localized radiation therapy to the index tumor\n* Concurrent treatment for RCC or treatment in the last 6 months in another clinical study, unless it is an observational study (non-interventional) or during a non-interventional follow-up stage of an interventional study, or prior randomization to this study\n* History of active primary\u002Facquired immunodeficiency\n* Presence of renal ureteral stent in the treatment kidney at any time\n* History of malignancy, other than RCC, within three years, with the exception of adequately treatment carcinoma in situ of the cervix, early squamous cell carcinoma or basal cell carcinoma of the skin, localized prostate cancer, ductal carcinoma in situ, or low-grade endometrial carcinoma with no myometrial invasion (negligible risk of metastases or death 5-year overall survival \\[OS\\] rate \\> 90%)\n* Major surgical procedure (as defined by the Investigator) within 28 days prior to enrollment\n* A history of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically\n* Active infection\n* Female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 6 months after treatment\n* Unstable chronic disease or evidence of any disease or condition that would place the patient at undue risk and preclude safe use of Y90 microspheres, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent\n* History of pulmonary insufficiency, measured by oxygen saturation of less than 90%\n* Solitary kidney\n* Patient not able to follow the study protocol requirements","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This phase I\u002FII trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.",[27,28],"Stage I Renal Cell Cancer","Stage II Renal Cell Cancer","RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2024-12-26",{"date":37,"type":20},"2030-03",{"name":39,"class":40},"Jonsson Comprehensive Cancer Center","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100550440","phase-2-an-investigational-scan-89zr-dfo-gmab-petct-compared-to-contrast-enhanced-ct-for-the-detection-of-recurrent-clear-cell-renal-cell-cancer-after-surgery-comparing-carbonic-anhydrase-ix-caix-pet-ct-to-conventional-pet-ct-for-post-op-staging-in-kidney-cancer-100550440","NCT06447103","An Investigational Scan (89Zr-DFO-GmAb PET\u002FCT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer","89Zr-DFO-GmAb PET\u002FCT vs Contrast-Enhanced CT for Detection of Recurrent Clear Cell Renal Cell Carcinoma After Surgery","Inclusion Criteria:\n\n* Age ≥ 18\n* Histologically confirmed clear cell renal cell carcinoma (RCC) (ccRCC) (based on partial\u002Fradical nephrectomy\u002Fmetastasectomy)\n\n  * For tumors with extensive sarcomatoid features, if there is evidence of areas of clear cell and high CAIX expression throughout the tumor on immunohistochemistry, they will be allowed on study\n* Subjects must have undergone definitive treatment of their primary tumor (partial\u002Fradical nephrectomy) +\u002F- resection of metastatic disease to no evidence of disease (NED) with a prior nephrectomy \\\u003C 2 years)\n* Surgery must have been performed between 4-16 weeks at the time of planned imaging\n* Subjects are considered to have a high risk of recurrence based on the following criteria:\n\n  * Intermediate-high risk ccRCC:\n\n    * pathologic tumor stage 2 (pT2), grade 4, or sarcomatoid, N0, M0\n    * pathologic tumor stage 3 (pT3), any grade, N0, M0\n  * High risk ccRCC:\n\n    * pathologic tumor stage 4 (pT4), any grade, N0, M0\n    * pT any stage, any grade, number of positive nodes (pN+), M0\n  * M1 now NED: pathologically-confirmed ccRCC, undergoing a resection of a solitary, isolated soft tissue metastasis within two years from initial nephrectomy\n* Negative serum pregnancy tests in female patients of childbearing potential. (Women of child bearing potential \\[WOCBP\\] require a negative pregnancy test within 24 hours (urine) prior to receiving investigational product)\n* Consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-DFO-GmAb administration\n* Individual must be able to remain still and lie flat for duration of the diagnostic imaging procedure (less than 1 hour)\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Any evidence of residual disease or known metastasis at the time of planned 89Zr-DFO-GmAb administration\n* Prior post-operative imaging for confirmation of disease status\n* An untreated non-renal malignancy with the following exceptions:\n\n  * Low risk prostate cancer on active surveillance (National Comprehensive Cancer Network \\[NCCN\\] very low\u002Flow risk)\n  * Non-melanoma skin cancer\n* Any prior treated malignancy meeting the following characteristics:\n\n  * Treated stage I or II cancer from which the patient is currently in complete remission\n  * A stage III cancer from which the patient is progressing or has been disease-free for and has required active treatment (e.g. adjuvant or maintenance therapy) within the past 3 years prior to enrollment\n  * A hematologic malignancy from which the patient is currently in complete remission\n* Contraindication to the use of iodinated contrast-enhanced CT agents, based on:\n\n  * Severe allergy (for which pre-medication cannot limit adverse reactions) or\n  * Estimated glomerular filtration rate (GFR) ≤ 30 ml\u002Fmin\u002F1.73m\\^2\n* Prior use of systemic therapy treatment for kidney cancer (PD-1, PD-L1, tyrosine kinase or TOR inhibitor) or radiotherapy within 4 weeks of enrollment\n* Exposure to experimental diagnostic or therapeutic drug within 14 days from date of planned administration\n* Women who are pregnant or breastfeeding\n* Known hypersensitivity to girentuximab\n* Known inability to remain still and lie flat imaging procedure (about 30 minutes)",{"count":50,"type":20},91,[24],"This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)\u002Fcomputed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that has come back (recurrent). For some patients, the risk of recurrence after surgery remains high. Conventional CT methods, such as contrast-enhanced CT, may not detect small volume or micrometastatic disease. PET\u002FCT with radiotracers, such as 89Zr-DFO-GmAb, may improve detection of tumor cells. Girentuximab (GmAb), a monoclonal antibody, is tagged with zirconium-89, a radioactive atom (which is also known as an isotope). The zirconium-89 (89Zr) isotope is attached to girentuximab with desferrioxamine (DFO) and this combined product is called 89Zr-DFO-girentuximab. 89Zr-DFO-girentuximab attaches itself to a protein on the surface of clear cell renal cell tumor cells called CAIX. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 89Zr-DFO-GmAb. Because some cancers, including clear cell renal cell cancer, take up 89Zr-DFO-GmAb it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. Using contrast agents with CT scan to enhance the images (contrast-enhanced CT) is standard of care imaging. 89Zr-DFO-GmAb PET\u002FCT may be safe and effective compared to contrast-enhanced CT in detecting recurrent clear cell renal cell cancer after surgery.",[54,55,28,56,57],"Clear Cell Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer",[59],"Renal","2026-06-11",{"date":62,"type":33},"2026-06-15",{"date":64,"type":33},"2024-08-06",{"date":66,"type":20},"2030-12-01",{"name":39,"class":40},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":68},"100398870","phase-1-interstitial-brachytherapy-for-the-treatment-of-unresectableunablatable-kidney-cancer-100398870","NCT04473781","Interstitial Brachytherapy for the Treatment of Unresectable\u002FUnablatable Kidney Cancer","Prospective Study of Interstitial Brachytherapy for Unresectable\u002FUnablatable T1b\u002FT2a Renal Masses","Inclusion Criteria:\n\n* Elected to undergo interstitial brachytherapy as part of conventional treatment for renal cell carcinoma\n* Biopsy proven renal cell carcinoma\n* No definitive evidence of locally advanced (nodal or tumor thrombus) or distant (metastatic) disease\n* Lesion size (maximal dimension) of 4 to 10 cm\n* Patient not a candidate for curative surgery (unwilling or unable to pursue surgery)\n* Lesion cannot be reliably treated with ablative techniques\n* Entire lesion able to be treated adequately by brachytherapy per radiation oncologist\n* Tumor predominantly solid (\\~ \\> 80%)\n* Lesion that has been observed for \\>= 6 months with demonstrable growth rate anticipated to be \\>= 4 mm\u002Fyear by same imaging modality\n* Renal tumor that is amenable to percutaneous access for interstitial renal brachytherapy (Institutional Review Board \\[IRB\\])\n* Hemoglobin \\> 9\n* Absolute neutrophil count (ANC) \\>= 1500\u002FuL (microliter)\n* Platelets \\>= 100,000\u002FuL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 3.0 upper limit of normal (ULN)\n* Total bilirubin =\\\u003C ULN\n* A competent immune system\n* Estimated glomerular filtration rate (eGFR) \\>= 30\n* Good performance status (Eastern Cooperative Oncology Group \\[ECOG\\]) \\\u003C 2\n* Understanding and willingness to provide consent\n* No prior systemic treatment for kidney cancer\n* Women of childbearing potential must have negative pregnancy test at start of therapy\n\nExclusion Criteria:\n\n* Presence of an active, untreated, non-renal malignancy\n* Uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction within 6 months\n* History of bleeding diathesis or recent bleeding episode\n* Need for urgent treatment of renal cancer due bleeding, pain, or paraneoplastic syndrome\n* Prior surgery or radiation therapy to the operative site\n* Unwillingness to undergo clinical and laboratory monitoring and\u002For imaging studies",{"count":77,"type":20},17,[23],"This phase I\u002FII trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable\u002Funablatable). Brachytherapy, also known as internal radiation therapy, temporarily introduces a radiation source into or near the tumor to eradicate the tumor cells. Giving brachytherapy may potentially reduce the size of the kidney cancer mass that would otherwise not be amenable to surgical management and translate into lower risk of spread.",[27,28],"2026-02-26",{"date":83,"type":33},"2026-03-02",{"date":85,"type":33},"2020-07-16",{"date":87,"type":20},"2027-06-30",{"name":39,"class":40}]